๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX ยท Real-Time Price ยท USD
11.07
+0.04 (0.36%)
Nov 20, 2026, 4:00 PM EST - Market closed

MoonLake Immunotherapeutics Earnings Call Transcripts

Fiscal Year 2026

  • Investor Day 2026

    Sonelokimab's phase III data in HS show leading efficacy, safety, and convenience, supporting a broad label and BLA submission by end of Q3. Commercial preparations are advanced for a large, underpenetrated market, with strong prescriber and stakeholder enthusiasm. Priority review and pediatric labeling are possible.

  • Investor Day 2026

    Regulatory clarity enables BLA submission for SLK in HS with strong efficacy and safety data, while S-OLARIS and VELA programs show leading clinical outcomes and long-term benefits. Financial position supports ongoing development and commercial launch preparations.

Fiscal Year 2025

  • R&D Day 2025

    Sonelokimab showed robust efficacy and safety in phase 3 HS trials, with strong patient-reported outcomes and a favorable safety profile. Despite a high placebo response in one trial, management is confident in regulatory approval and market competitiveness, supported by a strong financial position.

  • CMD 2025

    Sonelokimab's phase III HS program completed rapid recruitment with strong baseline alignment to prior pivotal trials, supporting high confidence in efficacy replication. The company is well-funded, targeting a large, underpenetrated market, and differentiates through efficacy, convenience, and safety. Commercial focus is on the US, with ex-US options open.

Fiscal Year 2024

Fiscal Year 2023